Literature DB >> 23770493

Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users.

Ryan P Westergaard1, Timothy Hess, Jacquie Astemborski, Shruti H Mehta, Gregory D Kirk.   

Abstract

OBJECTIVE: To examine temporal trends and predictors of linkage to HIV care, longitudinal retention in care and viral suppression among injection drug users (IDUs) infected with HIV.
DESIGN: Community-based, prospective cohort study.
METHODS: We prospectively studied 790 HIV-infected IDUs participating in the AIDS Linked to the Intravenous Experience (ALIVE) study from 1998 through 2011. IDUs were considered linked to care if they attended any HIV care visit during follow-up and retained in care if they reported HIV clinic attendance at every semi-annual study visit. We used logistic regression to identify predictors of poor retention in care and failure to achieve sustained viral suppression in response to ART.
RESULTS: Of 790 HIV-infected IDUs studied, 740 (93.6%) were ever linked to care. The majority of IDUs (76.7%) received ART at some point during observation and of these, most (85.4%) achieved viral suppression. However, over a median of 8.7 years of follow-up, only 241 (30.5%) IDUs were continuously retained with no 6-month lapses in HIV care and only 63 (10.2%) had sustained viral suppression at every study visit after first receiving ART. Suboptimal engagement in care was associated with poor access to medical care, active drug use, and incarceration.
CONCLUSION: Compared with national estimates of retention in care and virologic suppression in the United States, IDUs are substantially less likely to remain fully engaged in HIV care. Strategies to optimize HIV care should acknowledge the elevated risk of poor engagement in care among IDUs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23770493      PMCID: PMC3795966          DOI: 10.1097/QAD.0b013e328363bff2

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  34 in total

1.  Incidence and risk factors associated with lost to follow-up in a Belgian cohort of HIV-infected patients treated with highly active antiretroviral therapy.

Authors:  T Schepens; S Morreel; E Florence; O Koole; R Colebunders
Journal:  Int J STD AIDS       Date:  2010-11       Impact factor: 1.359

2.  Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV?

Authors:  Mary Catherine Beach; Jeanne Keruly; Richard D Moore
Journal:  J Gen Intern Med       Date:  2006-06       Impact factor: 5.128

3.  Vital signs: HIV prevention through care and treatment--United States.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-12-02       Impact factor: 17.586

4.  Factors associated with the failure of HIV-positive persons to return for scheduled medical visits.

Authors:  Claudio Arici; Diego Ripamonti; Franco Maggiolo; Marco Rizzi; Maria Grazia Finazzi; Patrizio Pezzotti; Fredy Suter
Journal:  HIV Clin Trials       Date:  2002 Jan-Feb

5.  Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.

Authors:  D D Celentano; N Galai; A K Sethi; N G Shah; S A Strathdee; D Vlahov; J E Gallant
Journal:  AIDS       Date:  2001-09-07       Impact factor: 4.177

6.  Entry and retention in medical care among HIV-diagnosed persons: a meta-analysis.

Authors:  Gary Marks; Lytt I Gardner; Jason Craw; Nicole Crepaz
Journal:  AIDS       Date:  2010-11-13       Impact factor: 4.177

7.  Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice.

Authors:  Richard D Moore; John G Bartlett
Journal:  Clin Infect Dis       Date:  2011-08-14       Impact factor: 9.079

8.  Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.

Authors:  Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall
Journal:  Lancet       Date:  2010-07-16       Impact factor: 79.321

9.  U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008.

Authors:  Keri N Althoff; Kate Buchacz; H Irene Hall; Jinbing Zhang; David B Hanna; Peter Rebeiro; Stephen J Gange; Richard D Moore; Mari M Kitahata; Kelly A Gebo; Jeffrey Martin; Amy C Justice; Michael A Horberg; Robert S Hogg; Timothy R Sterling; Angela Cescon; Marina B Klein; Jennifer E Thorne; Heidi M Crane; Michael J Mugavero; Sonia Napravnik; Gregory D Kirk; Lisa P Jacobson; John T Brooks
Journal:  Ann Intern Med       Date:  2012-09-04       Impact factor: 25.391

10.  Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts.

Authors:  John D Morris; Elizabeth T Golub; Shruti H Mehta; Lisa P Jacobson; Stephen J Gange
Journal:  AIDS Res Ther       Date:  2007-06-06       Impact factor: 2.250

View more
  64 in total

1.  Identifying, linking, and treating people who inject drugs and were recently infected with HIV in the context of a network-based intervention.

Authors:  Mina Psichogiou; George Giallouros; Katerina Pantavou; Eirini Pavlitina; Martha Papadopoulou; Leslie D Williams; Andria Hadjikou; Eleni Kakalou; Athanasios Skoutelis; Konstantinos Protopapas; Anastasia Antoniadou; George Boulmetis; Dimitrios Paraskevis; Angelos Hatzakis; Samuel R Friedman; Georgios K Nikolopoulos
Journal:  AIDS Care       Date:  2019-04-02

2.  Recent Substance Use and Probability of Unsuppressed HIV Viral Load Among Persons on Antiretroviral Therapy in Continuity Care.

Authors:  Catherine R Lesko; Alexander P Keil; Anthony T Fojo; Geetanjali Chander; Bryan Lau; Richard D Moore
Journal:  Am J Epidemiol       Date:  2019-10-01       Impact factor: 4.897

3.  Patterns of Substance Use and Arrest Histories Among Hospitalized HIV Drug Users: A Latent Class Analysis.

Authors:  Karen Shiu-Yee; Ahnalee M Brincks; Daniel J Feaster; Jemima A Frimpong; Ank Nijhawan; Raul N Mandler; Robert Schwartz; Carlos Del Rio; Lisa R Metsch
Journal:  AIDS Behav       Date:  2018-09

4.  Response to: The relationship of physical performance with HIV disease and mortality: a cohort study.

Authors:  Daisson José Trevisol; Alexandre Da Silva; Clávison Martinelli Zapelini; Fabiana Schuelter-Trevisol; Fabricio De Souza
Journal:  AIDS       Date:  2015-03-27       Impact factor: 4.177

5.  Frailty, Inflammation, and Mortality Among Persons Aging With HIV Infection and Injection Drug Use.

Authors:  Damani A Piggott; Ravi Varadhan; Shruti H Mehta; Todd T Brown; Huifen Li; Jeremy D Walston; Sean X Leng; Gregory D Kirk
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2015-09-18       Impact factor: 6.053

Review 6.  Challenges in managing HIV in people who use drugs.

Authors:  Adeeba Kamarulzaman; Frederick L Altice
Journal:  Curr Opin Infect Dis       Date:  2015-02       Impact factor: 4.915

7.  Explanatory Models and Illness Experience of People Living with HIV.

Authors:  M Barton Laws
Journal:  AIDS Behav       Date:  2016-09

8.  HIV care continuum among men who have sex with men and persons who inject drugs in India: barriers to successful engagement.

Authors:  Shruti H Mehta; Gregory M Lucas; Suniti Solomon; Aylur K Srikrishnan; Allison M McFall; Neeraj Dhingra; Paneerselvam Nandagopal; M Suresh Kumar; David D Celentano; Sunil S Solomon
Journal:  Clin Infect Dis       Date:  2015-08-06       Impact factor: 9.079

9.  Incarceration of people living with HIV/AIDS: implications for treatment-as-prevention.

Authors:  M-J Milloy; Julio S G Montaner; Evan Wood
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

Review 10.  The paradigm of universal access to HIV-treatment and human rights violation: how do we treat HIV-positive people who use drugs?

Authors:  Monica Malta; Michelle Ralil da Costa; Francisco Inácio Bastos
Journal:  Curr HIV/AIDS Rep       Date:  2014-03       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.